TY - JOUR
T1 - Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction
AU - van der Spoel, T. I. G.
AU - Gathier, W. A.
AU - Koudstaal, S.
AU - van Slochteren, F.
AU - of Lorkeers, S. Jansen
AU - Sluijter, J. P. G.
AU - Hoefer, I. E.
AU - Steendijk, P.
AU - Cramer, M. J. M.
AU - Doevendans, P. A.
AU - van Belle, E.
AU - Chamuleau, S. A. J.
PY - 2015/9/17
Y1 - 2015/9/17
N2 - Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.
AB - Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84945440244&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/26382088
U2 - https://doi.org/10.1007/s12265-015-9643-3
DO - https://doi.org/10.1007/s12265-015-9643-3
M3 - Article
C2 - 26382088
SN - 1937-5387
VL - 8
SP - 393
EP - 403
JO - Journal of cardiovascular translational research
JF - Journal of cardiovascular translational research
IS - 7
ER -